Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Auxiliary therapeutic agent for C type hepatitis

A technology for adjuvant therapy, hepatitis, applied in the field of therapeutic agents

Inactive Publication Date: 2005-04-20
TCM BIOTECH INT CORP
View PDF2 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The current treatment for hepatitis C, the combination therapy of interferon combined with antiviral drug Ribavirin, has better curative effect than interferon alone. However, only 18% of patients achieve persistent viral infection after treatment Of course, if the course of interferon therapy is extended to one year, the continuous virus clearance can be increased to 30%, but the side effects and cost of the drug are still unbearable for patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Auxiliary therapeutic agent for C type hepatitis
  • Auxiliary therapeutic agent for C type hepatitis
  • Auxiliary therapeutic agent for C type hepatitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0010] In order to achieve the above object, the hepatitis C adjuvant therapeutic agent provided by the present invention is used in conjunction with hepatitis C compound therapy (interferon and Ribavirin) to treat hepatitis C, comprising:

[0011] Cordyceps sinensis with a weight ratio of 50 to 90 and

[0012] Tragacanth (Astragalus memsrancens) in a weight ratio of 10 to 50.

[0013] Wherein, Cordyceps sinensis refers to the submerged fermentation culture of its anamorphic Hirsutella sinensis mycelium.

[0014] Wherein, Cordyceps sinensis refers to the mycelium (bacteria) obtained by separating and purifying Cordyceps sinensis, including:

[0015] Paecilomyces sinensi, Chrysosporium sinense, Sporothrix insectorum, Stachybotrys sp., Tolypocladium sp., Paecilomyces bat Submerged fermentation culture of mycelia such as Trichosporum of bat moth.

[0016] Among them, the preferred weight ratio of Cordyceps sinensis is 70 to 80, and that of tragacanth is 20 to 30.

[0017] Amo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A auxiliary therapeutic agent for hepatitis C combined treating with a complex therapeutic method (interferon and Ribavirin)for hepatitis C, which is composed of (by weight) 50-90 part of Chinese caterpillar fungus and 10-50 part of astragalus. Said invention can adjust immune function of patient and improve curative effect for hepatitis C.

Description

technical field [0001] The invention relates to a therapeutic agent having components of cordyceps sinensis and tragacanth as an auxiliary treatment for hepatitis C, which can be combined with compound therapy for hepatitis C (interferon and Ribavirin) to improve the cure rate of hepatitis C. Background technique [0002] Hepatitis C virus is an RNA virus, discovered in 1989, formerly known as Non-A, Non-B hepatitis (Non-A, Non-B hepatitis), mostly caused by blood transfusion. , All blood is screened in advance, and the incidence rate is greatly reduced. [0003] According to Okamoto's classification, hepatitis C is divided into four genotypes: I, II, III, and IV. In Taiwan, hepatitis C is mainly geno type II, accounting for about 73%, followed by type III accounting for 13% and type IV accounting for 3%. Treatment of hepatitis C with interferon is more effective for types III and IV and less effective for types II and I. The viral clearance rate of interferon alone in the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/21A61P1/16A61P31/12
Inventor 柯万盛
Owner TCM BIOTECH INT CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com